Clinical Trial Update: Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is planned to evaluate the efficacy and safety of PN-101, an allogeneic mitochondrial therapy, in patients with refractory polymyositis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Polymyositis

Drugs mentioned

• PN-101

Snippet

Sponsor: Paean Biotechnology Inc. | Conditions: Polymyositis, Dermatomyositis | Phase 2 | Status: NOT_YET_RECRUITING